This study will determine if ingestion of 3 g/d betaine versus placebo for two weeks prior to a 60-km cycling time trial will improve performance, moderate exercise-induced gut permeability, and improve metabolic recovery.

开始日期2024-08-13

申办/合作机构

Appalachian State University

[+1]

RBR-2bd7gnb

/ Not yet recruitingN/AIIT

Chronic effects of Betaine supplementation on Lipid and Glycemic profile, Anthropometric and Cardiovascular parame-ters, and on Physical Exercise practice in adults engaged in Weightlifting: a randomized, double-blind, placebo-contro-lled study -

开始日期2024-06-10

申办/合作机构

Universidade Federal de Juiz de Fora

[+1]

100 项与无水甜菜碱相关的临床结果

登录后查看更多信息

100 项与无水甜菜碱相关的转化医学

登录后查看更多信息

100 项与无水甜菜碱相关的专利（医药）

登录后查看更多信息

15,201

项与无水甜菜碱相关的文献（医药）

2025-12-01·Molecular Biology Reports

Growth, physiological and molecular response of calcium and salicylic acid primed wheat under lead stress

Article

作者: Aseel, Dalia G ; Abo-Kassem, Essam-Eldeen M ; Saad-Allah, Khalil M ; Hafez, Elsayed E ; Sobhy, Sherien E ; Sewelam, Nasser A ; Saleh, Ahmed A

BACKGROUNDHeavy metal contamination, particularly from lead (Pb), poses a significant threat to plant agriculture worldwide, adversely affecting growth, physiological functions, and yield. Signalling molecules such as calcium and salicylic acid are known to mitigate various stresses in plants, prompting this study to explore their interaction with Pb stress in wheat.METHODSA pot experiment was conducted in which wheat grains were primed with either distilled water, 5 mM calcium (Ca), or 0.05 mM salicylic acid (SA) for 12 h. Following germination, seedlings were exposed to 100 mM Pb six days later, while the control group received water irrigation. Growth parameters, physiological changes, molecular responses, and yield characteristics were assessed to understand the impact of the treatments.RESULTSThe application of Ca and SA acid significantly ameliorated Pb-induced reductions in growth parameters, yield criteria, and phenolic content. These treatments also reduced oxidative stress by restoring osmoprotectants, Pb ion content, and antioxidant enzyme activities to normal levels. Additionally, they downregulated genes that were overexpressed in Pb-stressed wheat.CONCLUSIONSCa and SA treatments effectively mitigate lead toxicity in wheat by protecting growth, enhancing physiological resilience, and maintaining productivity. These findings suggest that leveraging chemical stimulants such as calcium and salicylic acid constitutes a viable strategy for reducing the detrimental impacts of heavy metal stress on crop yields.

2025-08-01·Talanta

Intelligent characterization multi-components in Yangxinshi tablet by online comprehensive two-dimensional liquid chromatography-quadrupole time-of-flight mass spectrometry combined with deep learning-assisted mass defect filtering classification and multidimensional data annotation strategy

Article

作者: Du, Kunze ; Li, Jin ; Chen, Shujing ; Chang, Yanxu ; Zhang, Lili ; Wei, Wei ; Wen, Jiake ; Wang, Xiaoyan ; Xu, Jixiang

A comprehensive characterization strategy for the intelligent analysis of multiple chemical components in Yangxinshi Tablet (YXST) was established. The strategy developed the deep learning-assisted mass defect filtering intelligent classification, preferred ions capture list and active exclusion (DLA-MDF-PIL-AE) data acquisition mode by online comprehensive two-dimensional liquid chromatography coupled with quadrupole time-of-flight mass spectrometry (2DLC-Q-TOF-MS/MS). Firstly, the online 2DLC-Q-TOF-MS/MS system was constructed and the orthogonality was evaluated. Secondly, the user interface for deep learning-assisted MDF intelligent classification technology was developed and applied to compounds classification to generate preferred ion capture lists of various types compounds. Finally, molecular networking (MN), associated neutral loss (NL) fragments, and characteristic diagnosis ion (CDI) were utilized for the automatic and manual annotation of compounds, respectively. As a result, a total of 228 compounds including 80 flavanoids, 52 alkaloids, 36 phenolic acids, 15 terpenoids, 17 saponins and 28 others were preliminary identified from YXST and source attribution was assigned to them. Furthermore, 39 compounds were simultaneously quantified by ultra-high performance liquid chromatography coupled with triple quadrupole mass spectrometry (UHPLC-MS/MS) method. Conclusively, the proposed integrated strategy proved to be a powerful method for characterizing multiple components in complex natural products.

2025-08-01·Food Chemistry

Investigation into the effects of acute heat stress on stress level, meat quality, myofibrillar proteins properties and serum metabolites release of Muscovy ducks (Cairina moschata)

Article

作者: Huang, Ming ; Li, Zimu ; Huang, Jichao ; Zhu, Zongshuai ; Huang, Tianran ; Xiao, Mengchao

This study systematically investigated the effects of acute heat stress (AHS) on Muscovy ducks, focusing on plasma stress indicators, meat quality, myofibrillar proteins (MPs) properties, and serum metabolite profiles. AHS significantly elevated stress level, impairing meat quality, as evidenced by higher L* value, shear force, drip loss, and cooking loss (P < 0.05). It also induced MPs oxidation and aggregation, reflected by elevated carbonyl content, turbidity, zeta potential, and particle size. MPs structural alterations were confirmed by fluorescence quenching and increased exposure of hydrophobic groups. Correlation analysis revealed strong associations between physicochemical changes and MPs oxidation. Metabolomic analysis identified 161 and 105 differential metabolites in the CON vs. LS and CON vs. SS comparisons, respectively, involving 25 metabolic pathways related to energy, amino acids, and fatty acids. These findings provide novel insights into the molecular pathways of AHS-induced meat quality deterioration and reveal potential intervention timing for the poultry industry.

项与无水甜菜碱相关的新闻（医药）

2025-04-28

·GlobeNewswire-Health Care

Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution)

- NDA submitted for the treatment of central diabetes insipidus -- Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch – DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ET-600, Eton’s proprietary, patented oral solution of desmopressin under development for the treatment of central diabetes insipidus. The Company expects the application to be assigned a 10-month FDA review, allowing for potential approval and launch in the first quarter of 2026. “The NDA submission for ET-600 is another important milestone for Eton, and for the thousands of children impacted by diabetes insipidus. If approved, ET-600 will be the only FDA-approved oral liquid formulation of desmopressin, providing the small, precise, and titratable doses required to treat pediatric patients,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “Leading pediatric endocrinologists have long expressed a need for this product, and we’re pleased to be one step closer to bringing it to patients. Pre-launch commercial activities are already underway as we plan for a potential approval in the first quarter of 2026.” Eton has been issued a patent by the U.S. Patent and Trademark Office on ET-600, which expires in 2044 and has additional patent applications under review. In a bioequivalence study conducted in 75 human subjects, ET-600 demonstrated pharmacokinetic equivalence to the FDA-approved reference product of the same active ingredient. The company estimates that central diabetes insipidus impacts approximately 3,000 pediatric patients in the United States. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Relations:Lisa M. Wilson, In-Site Communications, Inc.T: 212-452-2793E: lwilson@insitecony.com Source: Eton Pharmaceuticals, Inc.

申请上市

2025-04-28

·ir.etonpharma.com

Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution) | Eton Pharmaceuticals, Inc.

News Release Details « Back to news Eton Pharmaceuticals Announces Submission of NDA for ET-600 (Desmopressin Oral Solution) - NDA submitted for the treatment of central diabetes insipidus - - Expected 10-month review; commercial preparations underway for a potential Q1 2026 launch – DEER PARK, Ill., April 28, 2025 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (“Eton” or the “Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for ET-600, Eton’s proprietary, patented oral solution of desmopressin under development for the treatment of central diabetes insipidus. The Company expects the application to be assigned a 10-month FDA review, allowing for potential approval and launch in the first quarter of 2026. “The NDA submission for ET-600 is another important milestone for Eton, and for the thousands of children impacted by diabetes insipidus. If approved, ET-600 will be the only FDA-approved oral liquid formulation of desmopressin, providing the small, precise, and titratable doses required to treat pediatric patients,” said Sean Brynjelsen, CEO of Eton Pharmaceuticals. “Leading pediatric endocrinologists have long expressed a need for this product, and we’re pleased to be one step closer to bringing it to patients. Pre-launch commercial activities are already underway as we plan for a potential approval in the first quarter of 2026.” Eton has been issued a patent by the U.S. Patent and Trademark Office on ET-600, which expires in 2044 and has additional patent applications under review. In a bioequivalence study conducted in 75 human subjects, ET-600 demonstrated pharmacokinetic equivalence to the FDA-approved reference product of the same active ingredient. The company estimates that central diabetes insipidus impacts approximately 3,000 pediatric patients in the United States. About Eton Pharmaceuticals Eton is an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases. The Company currently has seven commercial rare disease products: INCRELEX®, ALKINDI SPRINKLE®, GALZIN®, PKU GOLIKE®, Carglumic Acid, Betaine Anhydrous, and Nitisinone. The Company has six additional product candidates in late-stage development: ET-400, ET-600, Amglidia®, ET-700, ET-800 and ZENEO® hydrocortisone autoinjector. For more information, please visit our website at www.etonpharma.com. Forward-Looking Statements Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, including statements associated with the expected ability of Eton to undertake certain activities and accomplish certain goals and objectives. These statements include but are not limited to statements regarding Eton’s business strategy, Eton’s plans to develop and commercialize its product candidates, the safety and efficacy of Eton’s product candidates, Eton’s plans and expected timing with respect to regulatory filings and approvals, and the size and growth potential of the markets for Eton’s product candidates. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Words such as “believes,” “anticipates,” “plans,” “expects,” “intends,” “will,” “goal,” “potential” and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon Eton’s current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks associated with the process of discovering, developing and commercializing drugs that are safe and effective for use as human therapeutics, and in the endeavor of building a business around such drugs. These and other risks concerning Eton’s development programs and financial position are described in additional detail in Eton’s filings with the Securities and Exchange Commission. All forward-looking statements contained in this press release speak only as of the date on which they were made. Eton undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investor Relations: Lisa M. Wilson, In-Site Communications, Inc. T: 212-452-2793 E: lwilson@insitecony.com Source: Eton Pharmaceuticals, Inc. Source: Eton Pharmaceuticals

申请上市

2025-04-13

·信狐药迅

恒瑞医药-夫那奇珠单抗注射液银屑病新适应症获批上市| 新获批(4.7-4.13）

每周药品注册获批数据，分门别类呈现，一目了然。(4.7-4.13）新药上市申请药品名称企业注册分类受理号SHR0302片江苏恒瑞医药股份有限公司1CXHS2300097夫那奇珠单抗注射液苏州盛迪亚生物医药有限公司1CXSS2400018夫那奇珠单抗注射液苏州盛迪亚生物医药有限公司1CXSS2400017新药临床申请药品名称企业注册分类受理号注射用BH259珠海贝海生物技术有限公司1CXHL2500168HRS9531注射液福建盛迪医药有限公司1CXHL2500157HRS9531注射液福建盛迪医药有限公司1CXHL2500156HRS9531注射液福建盛迪医药有限公司1CXHL2500155HRS-9813胶囊广东恒瑞医药有限公司1CXHL2500147TM471-1胶囊知微生物医药(新乡)有限公司1CXHL2500137TM471-1胶囊知微生物医药(新乡)有限公司1CXHL2500136AC699片冰洲石生物科技(上海)有限公司1CXHL2500145AC699片冰洲石生物科技(上海)有限公司1CXHL2500142TQB3019胶囊正大天晴药业集团股份有限公司1CXHL2500138TT-9701片中国科学院上海药物研究所1CXHL2500129TT-9701片中国科学院上海药物研究所1CXHL2500128INR102注射液云核医药(天津)有限公司1CXHL2500121FY101注射液北京福元医药股份有限公司1CXHL2500100DNV001注射液杭州鼎乐新为生物科技有限公司1CXHL2500095奥格特韦钠胶囊浙江艾森药业有限公司1CXHL2500093SYH2046片上海翊石医药科技有限公司1CXHL2500091SYH2046片上海翊石医药科技有限公司1CXHL2500090RN1871 注射液大睿生物医药科技(上海)有限公司1CXHL2500078注射用IMBZ18g广州艾奇西新药研究有限公司1CXHL2500053DM2065贴北京德默高科医药技术有限公司2.2CXHL2500148司美格鲁肽注射液海南中和药业股份有限公司2.2CXHL2500127司美格鲁肽注射液海南中和药业股份有限公司2.2CXHL2500126司美格鲁肽注射液海南中和药业股份有限公司2.2CXHL2500125司美格鲁肽注射液海南中和药业股份有限公司2.2CXHL2500124LH-2103胶囊江苏联环药业股份有限公司2.3CXHL2500114注射用西罗莫司(白蛋白结合型)石药集团中奇制药技术(石家庄)有限公司2.4CXHL2500134带状疱疹mRNA疫苗上海生物制品研究所有限责任公司1.2CXSL2500040AK139注射液中山康方生物医药有限公司1CXSL2500100AK139注射液中山康方生物医药有限公司1CXSL2500099BNT327百欧恩泰(上海)医药有限公司1CXSL2500096BNT326百欧恩泰(上海)医药有限公司1CXSL2500095注射用SIM0686上海先祥医药科技有限公司1CXSL2500097注射用QLS31905齐鲁制药有限公司1CXSL2500084ADG126注射液天演药业(苏州)有限公司1CXSL2500089注射用ZG005苏州泽璟生物制药股份有限公司1CXSL2500083注射用ASKG915江苏奥赛康生物医药有限公司1CXSL2500092SHR-1819注射液广东恒瑞医药有限公司1CXSL2500086SHR-4658注射液上海恒瑞医药有限公司1CXSL2500067EA5注射液上海览屹医药科技有限公司1CXSL2500051P134细胞注射液天士力医药集团股份有限公司1CXSL2500032XS411细胞注射液士泽生物医药(苏州)有限公司1CXSL2500035卡度尼利单抗注射液康方药业有限公司2.2CXSL2500102QL2107注射液齐鲁制药有限公司2.2CXSL2500085SHR-8068注射液苏州盛迪亚生物医药有限公司2.2CXSL2500088阿得贝利单抗注射液上海盛迪医药有限公司2.2CXSL2500093阿得贝利单抗注射液上海盛迪医药有限公司2.2CXSL2500081纳基奥仑赛注射液广东合源生物医药有限公司2.2CXSL2500030仿制药申请药品名称企业注册分类受理号法莫替丁注射液广州一品红制药有限公司3CYHS2401785盐酸纳美芬注射液福建新迪医药科技有限公司3CYHS2401361帕拉米韦注射液山东齐都药业有限公司3CYHS2400400氯化钾注射液福建新迪医药科技有限公司3CYHS2303635盐酸阿比多尔片武汉人福利康药业有限公司3CYHS2303169普瑞巴林口服溶液浙江浙北药业有限公司3CYHS2302826钠钾镁钙注射用浓溶液南京正科医药股份有限公司3CYHS2302809普瑞巴林口服溶液广西维威制药有限公司3CYHS2302626磷酸奥司他韦干混悬剂江苏加友药业集团有限公司3CYHS2302613生理氯化钠溶液山东科伦药业有限公司3CYHS2302543生理氯化钠溶液山东科伦药业有限公司3CYHS2302542福多司坦口服溶液昆明南疆制药有限公司3CYHS2302476复方匹可硫酸钠颗粒江西科睿药业有限公司3CYHS2302428氨茶碱注射液华夏生生药业(北京)有限公司3CYHS2302129昂丹司琼口溶膜江苏和晨药业有限公司3CYHS2302092昂丹司琼口溶膜江苏和晨药业有限公司3CYHS2302091依巴斯汀口服溶液海南元盈医药科技有限公司3CYHS2302066熊去氧胆酸口服混悬液成都赛璟生物医药科技有限公司3CYHS2302006洛索洛芬钠口服溶液云南先施药业有限公司3CYHS2301966氢溴酸依他佐辛注射液合肥亿帆生物制药有限公司3CYHS2301841复方聚乙二醇(3350)电解质散南京同仁堂黄山精制药业有限公司3CYHS2301730奥硝唑注射液海南海灵化学制药有限公司3CYHS2301608注射用苯唑西林钠广东金城金素制药有限公司3CYHS2301449注射用苯唑西林钠广东金城金素制药有限公司3CYHS2301448米诺地尔外用溶液江苏润邦药业有限公司3CYHS2301430米诺地尔外用溶液江苏润邦药业有限公司3CYHS2301429右酮洛芬氨丁三醇片湖南诺纳医药科技有限公司3CYHS2301107盐酸左西替利嗪口服溶液吉林省辉南长龙生化药业股份有限公司3CYHS2300981聚乙烯醇滴眼液浙江莎普爱思药业股份有限公司3CYHS2300976维生素K滴剂广西铭磊维生制药有限公司3CYHS2201025国;CYHS2201025复方氨基酸注射液(18AA-IX)辽宁民康制药有限公司4CYHS2500159沙美特罗替卡松吸入粉雾剂润生药业有限公司4CYHS2403268硫酸氢氯吡格雷片四川鲁徽制药有限责任公司4CYHS2400549西洛他唑片烟台万润药业有限公司4CYHS2400480硫酸氨基葡萄糖胶囊广州汇元医药科技有限公司4CYHS2400433达格列净片江苏万高药业股份有限公司4CYHS2400293达格列净片江苏万高药业股份有限公司4CYHS2400292甲磺酸多沙唑嗪缓释片四川科伦药业股份有限公司4CYHS2400244地夸磷索钠滴眼液武汉五景药业有限公司4CYHS2400230吸入用丙酸倍氯米松混悬液江西艾施特制药有限公司4CYHS2400132达格列净片福元药业有限公司4CYHS2303637达格列净片福元药业有限公司4CYHS2303636黄体酮软胶囊浙江神洲药业有限公司4CYHS2303548二甲双胍恩格列净片(VI)山东朗诺制药有限公司4CYHS2303456二甲双胍恩格列净片(I)山东朗诺制药有限公司4CYHS2303455注射用头孢他啶阿维巴坦钠成都倍特药业股份有限公司4CYHS2303429注射用替考拉宁福安药业集团烟台只楚药业有限公司4CYHS2303391注射用盐酸万古霉素海南倍特药业有限公司4CYHS2303276枸橼酸西地那非片遂成药业股份有限公司4CYHS2303272枸橼酸西地那非片遂成药业股份有限公司4CYHS2303271氧(液态)南宁市卓越气体有限公司4CYHS2303098复方氨基酸注射液(18AA-VII)山东齐都药业有限公司4CYHS2303086盐酸屈他维林注射液北京沃邦医药科技有限公司4CYHS2303060培哚普利叔丁胺片安若维他药业泰州有限公司4CYHS2302967培哚普利叔丁胺片安若维他药业泰州有限公司4CYHS2302966培哚普利叔丁胺片安若维他药业泰州有限公司4CYHS2302965盐酸贝尼地平片四川科瑞德制药股份有限公司4CYHS2302931长链脂肪乳注射液(OO)广东嘉博制药有限公司4CYHS2302821利丙双卡因乳膏浙江沣华医药科技有限公司4CYHS2302779乳果糖口服溶液哈药集团中药二厂4CYHS2302709缬沙坦氨氯地平片(I)河北万岁药业有限公司4CYHS2302651甲磺酸倍他司汀片厦门恩成制药有限公司4CYHS2302477左卡尼汀口服溶液东药集团沈阳施德药业有限公司4CYHS2302431骨化三醇软胶囊广州艾格生物科技有限公司4CYHS2302406沙库巴曲缬沙坦钠片沐邦(北京)医药科技有限公司4CYHS2302076沙库巴曲缬沙坦钠片沐邦(北京)医药科技有限公司4CYHS2302075沙库巴曲缬沙坦钠片沐邦(北京)医药科技有限公司4CYHS2302074头孢地尼颗粒重庆吉斯瑞制药有限责任公司4CYHS2302029硝酸甘油喷雾剂北京双鹭药业股份有限公司4CYHS2301947二甲双胍恩格列净片(I)杭州朱养心药业有限公司4CYHS2301801甲磺酸溴隐亭片浙江泰利森药业有限公司4CYHS2301125进口申请药品名称企业注册分类受理号盐酸伊普可泮胶囊Novartis Pharma Schweiz AG2.4JXHS2400061环索奈德吸入气雾剂Covis Pharma GmbH5.1JXHS2400019环索奈德吸入气雾剂Covis Pharma GmbH5.1JXHS2400018枸橼酸艾瑞芬净片SCYNEXIS, Inc.5.1JXHS2300072地诺孕素片Laboratoires Besins International5.2JYHS2400030注射用厄他培南Savior Lifetec Corporation5.2JYHS2300070布地奈德福莫特罗吸入气雾剂Mylan Pharmaceuticals Inc.5.2JYHS2300039布地奈德福莫特罗吸入气雾剂Mylan Pharmaceuticals Inc.5.2JYHS2300038MT-7117 片Mitsubishi Tanabe Pharma Corporation1JXHL2500014PF-07275315注射液Pfizer Inc.1JXSL2500035度伐利尤单抗注射液MedImmune LLC2.2JXSL2500018艾氟洛芬贴剂齐鲁制药有限公司3CYHL2500032氟比洛芬贴剂江西康恩贝中药有限公司3CYHL2500030双氯芬酸钠贴剂深圳珐玛易药品科技有限公司3CYHL2500027帕立骨化醇软胶囊青岛国信制药有限公司3CYHL2500029帕立骨化醇软胶囊青岛国信制药有限公司3CYHL2500028无水甜菜碱散剂伊春五加参药业有限责任公司3CYHL2500026瑞卢戈利片浙江和泽医药科技股份有限公司3CYHL2500017阿瑞匹坦注射液山东齐都药业有限公司3CYHL2500016尿素[13C]呼气试验药盒辐瑞森生物科技(昆山)有限公司3CYHL2500015尿素[13C]呼气试验药盒辐瑞森生物科技(昆山)有限公司3CYHL2500014甘露醇山梨醇注射液湖南先施制药有限公司3CYHL2500008皮下注射人免疫球蛋白华润博雅生物制药集团股份有限公司3.2CXSL2500031中药相关申请无注：橙色字体部分结论为不批准或收到通知件；

疫苗信使RNA申请上市上市批准临床申请

100 项与无水甜菜碱相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	无水甜菜碱	A16AA06	DB06756

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
同型半胱氨酸尿症	澳大利亚	Recordati SpA	1996-10-01

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
原发性高草酸尿症1型	临床2期	美国	National Institute of Diabetes & Digestive & Kidney Diseases	2007-02-01
天使综合征	临床前	美国	Rady Children's Hospital-San Diego	2011-12-01
天使综合征	临床前	美国	University of California	2011-12-01
天使综合征	临床前	美国	National Institutes of Health	2011-12-01
婴儿反流疾病	临床前	加拿大	Recordati SpA	-
Zellweger综合征	临床前	加拿大	Recordati SpA	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


EASD2022	N/A	-	-	Betaine	鹽積遞積餘遞遞築鑰獵(淵鹹顧鬱餘獵遞餘簾鏇) = 簾艱蓋繭壓簾餘夢窪壓鬱製觸膚廠餘夢網艱夢 (鑰願憲襯願製選蓋鹹餘 ) 更多	-	2022-09-22
				Control (BSA or palmitate)	鹽積遞積餘遞遞築鑰獵(淵鹹顧鬱餘獵遞餘簾鏇) = 願鏇顧構醖壓範餘窪糧鬱製觸膚廠餘夢網艱夢 (鑰願憲襯願製選蓋鹹餘 ) 更多
DDW2022	N/A	非酒精性脂肪性肝炎	-	BETAINE (Normal Chow Diet (NCD))	網網衊積襯衊鏇襯醖網(憲鏇簾糧遞衊餘鬱繭鬱) = 簾築醖艱獵膚壓廠選衊鏇選鑰範廠鏇製選鹽蓋 (壓齋鑰簾衊窪糧網糧齋 )	-	2022-05-23
NCT01950039 (CTgov)	临床2期	肥胖	28	Betaine (Betaine)	(餘鹽蓋鹹醖觸廠鏇齋醖) = 築鹹選襯齋網淵醖鹹鏇願憲糧鏇艱繭襯鑰鬱艱 (壓艱齋鬱壓憲壓齋醖積, 鏇網選觸窪壓醖顧鹽壓 ~ 鏇膚獵鹹選願膚願鹽積) 更多	-	2021-04-20
				Placebo (Placebo)	(餘鹽蓋鹹醖觸廠鏇齋醖) = 齋蓋鏇糧獵夢醖築衊廠願憲糧鏇艱繭襯鑰鬱艱 (壓艱齋鬱壓憲壓齋醖積, 觸鬱選醖遞膚製衊積選 ~ 鬱鑰構壓鏇夢鹽鹽鏇醖) 更多
NCT01838941 (CTgov)	临床3期	过氧化物酶体生物合成障碍	12	Betaine	積顧選範襯糧鬱簾範蓋(鏇襯網糧膚顧膚觸餘構) = 膚淵餘顧窪膚壓鑰餘蓋構鬱選蓋顧簾構網選簾 (憲衊範廠鏇鹽顧簾鹽夢, 鑰製簾鹹願膚膚糧鹽壓 ~ 積簾築壓網壓積糧鑰獵) 更多	-	2016-06-28
NCT01749982 (CABS, CTgov)	临床4期	-	60	Placebo (Placebo)	鏇衊窪構製積網積顧淵(繭夢蓋鹹繭選鬱鹽積鹽) = 夢範廠顧鬱衊簾衊積壓獵繭憲製網夢艱獵壓繭 (艱醖憲網壓窪襯遞製醖, 艱製窪網襯齋夢壓糧餘 ~ 鬱鏇構鹹壓鹽網製觸鹽) 更多	-	2014-08-28
				Choline bitartrate (Choline Bitartrate)	鏇衊窪構製積網積顧淵(繭夢蓋鹹繭選鬱鹽積鹽) = 糧繭艱選鬱鏇衊遞蓋憲獵繭憲製網夢艱獵壓繭 (艱醖憲網壓窪襯遞製醖, 廠範鹽鏇遞築鹹壓鏇廠 ~ 積鏇糧願餘糧選襯糧餘) 更多
NCT00283387 (CTgov)	临床2期	原发性高草酸尿症1型	15	Placebo+Betaine (Betaine)	選鹽糧選窪遞餘構製襯(遞廠簾蓋遞憲鑰範膚醖) = 範襯遞鬱衊餘廠範齋憲餘鹽夢築艱觸網繭壓壓 (鏇觸淵構膚壓遞簾網鹽, 積壓廠憲淵醖繭繭膚窪 ~ 願廠鏇築選簾醖淵築鹽) 更多	-	2013-01-01
				Placebo+Betaine (Placebo)	選鹽糧選窪遞餘構製襯(遞廠簾蓋遞憲鑰範膚醖) = 鹽餘鹹選憲鏇壓壓範獵餘鹽夢築艱觸網繭壓壓 (鏇觸淵構膚壓遞簾網鹽, 獵鬱鏇範齋窪夢衊窪顧 ~ 蓋網觸淵衊夢膚齋淵齋) 更多
NCT00348933 (CTgov)	N/A	天使综合征	90	Metafolin+B12+Creatine+Betaine (Treatment (Metafolin/Creatine/Betaine/B12))	遞鏇壓積鑰鏇夢餘鏇構(獵遞蓋積遞鏇艱鹹壓艱) = 鹽積鹹蓋夢壓窪遞窪鏇憲鏇鬱網觸鹽構鹹淵衊 (構醖壓網遞膚鏇壓鑰鹹, 膚鑰衊範鹹衊艱簾鹹築 ~ 鏇構餘鹽願壓構鹽築簾) 更多	-	2012-09-24
				Metafolin (Treatment (Metafolin/Creatine/Betain/B12))	構鹹繭壓鹹餘夢窪網淵(積餘壓遞鹹廠窪餘顧簾) = 窪壓廠窪鬱積網網積蓋醖憲齋鑰簾壓選鹹願艱 (遞繭鏇鹽膚選獵窪廠醖, 繭醖繭願築艱醖窪醖鹽 ~ 築繭夢鏇糧範構淵製醖) 更多
ASN2011	N/A	原发性高草酸尿症1型 AGXT genotypes \| I244T mutation	15	Betaine 10 gm	製簾網衊齋觸範網鬱積(獵觸顧鹽餘醖衊蓋壓鑰) = 積鹹夢積襯繭淵鬱積構構構淵繭夢窪選網鏇繭 (齋蓋構積衊獵糧選顧襯, 0.97)	不佳	2011-11-08
				Placebo	製簾網衊齋觸範網鬱積(獵觸顧鹽餘醖衊蓋壓鑰) = 憲夢夢膚壓膚顧齋鑰範構構淵繭夢窪選網鏇繭 (齋蓋構積衊獵糧選顧襯, 0.71)